CN105755112B - 结肠直肠癌的诊断 - Google Patents
结肠直肠癌的诊断 Download PDFInfo
- Publication number
- CN105755112B CN105755112B CN201511009181.5A CN201511009181A CN105755112B CN 105755112 B CN105755112 B CN 105755112B CN 201511009181 A CN201511009181 A CN 201511009181A CN 105755112 B CN105755112 B CN 105755112B
- Authority
- CN
- China
- Prior art keywords
- colorectal cancer
- kinds
- purposes
- biomarker
- m2pk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 95
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 92
- 238000003745 diagnosis Methods 0.000 title claims abstract description 42
- 239000000090 biomarker Substances 0.000 claims abstract description 163
- 238000001514 detection method Methods 0.000 claims abstract description 37
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims abstract description 34
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims abstract description 34
- 102000004890 Interleukin-8 Human genes 0.000 claims abstract description 30
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract description 30
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims abstract description 28
- 101710099550 Dickkopf-related protein 3 Proteins 0.000 claims abstract description 27
- 108090000176 Interleukin-13 Proteins 0.000 claims abstract description 24
- 102000003816 Interleukin-13 Human genes 0.000 claims abstract description 24
- 238000005259 measurement Methods 0.000 claims abstract description 23
- 102100040510 Galectin-3-binding protein Human genes 0.000 claims abstract description 20
- 101710197901 Galectin-3-binding protein Proteins 0.000 claims abstract description 20
- -1 M2PK Proteins 0.000 claims abstract description 19
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims abstract description 14
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims abstract description 14
- 101000815628 Homo sapiens Regulatory-associated protein of mTOR Proteins 0.000 claims abstract description 10
- 101000652747 Homo sapiens Target of rapamycin complex 2 subunit MAPKAP1 Proteins 0.000 claims abstract description 10
- 101000648491 Homo sapiens Transportin-1 Proteins 0.000 claims abstract description 10
- 102100028748 Transportin-1 Human genes 0.000 claims abstract description 10
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims abstract 3
- 230000035945 sensitivity Effects 0.000 claims description 61
- 150000001875 compounds Chemical class 0.000 claims description 31
- 210000002966 serum Anatomy 0.000 claims description 23
- 210000002381 plasma Anatomy 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 10
- 238000002965 ELISA Methods 0.000 claims description 9
- 238000007689 inspection Methods 0.000 claims description 8
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 7
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 7
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 102100030417 Matrilysin Human genes 0.000 claims description 4
- 108090000855 Matrilysin Proteins 0.000 claims description 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 4
- 210000003608 fece Anatomy 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims description 3
- 102100038778 Amphiregulin Human genes 0.000 claims description 3
- 108010033760 Amphiregulin Proteins 0.000 claims description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 3
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims description 3
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 3
- 101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 claims description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 3
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 3
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 3
- 102100037850 Interferon gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 102000003814 Interleukin-10 Human genes 0.000 claims description 3
- 108090000174 Interleukin-10 Proteins 0.000 claims description 3
- 102000004388 Interleukin-4 Human genes 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 3
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 claims description 3
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 3
- 101710108790 Stromelysin-1 Proteins 0.000 claims description 3
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 3
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims description 3
- 210000001772 blood platelet Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 2
- 102000001326 Chemokine CCL4 Human genes 0.000 claims description 2
- 108010055165 Chemokine CCL4 Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 2
- 210000002231 macronucleus Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 75
- 101150084967 EPCAM gene Proteins 0.000 abstract description 14
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 6
- 238000009007 Diagnostic Kit Methods 0.000 abstract description 2
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 43
- 239000012071 phase Substances 0.000 description 34
- 238000011160 research Methods 0.000 description 31
- 206010028980 Neoplasm Diseases 0.000 description 29
- 201000011510 cancer Diseases 0.000 description 26
- 238000012360 testing method Methods 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 21
- 229940096397 interleukin-8 Drugs 0.000 description 21
- 229920001184 polypeptide Polymers 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 238000002790 cross-validation Methods 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 239000003550 marker Substances 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 238000004422 calculation algorithm Methods 0.000 description 10
- 238000012216 screening Methods 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 7
- 238000002405 diagnostic procedure Methods 0.000 description 7
- 238000010369 molecular cloning Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 201000002313 intestinal cancer Diseases 0.000 description 5
- 239000013610 patient sample Substances 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000002052 colonoscopy Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000007637 random forest analysis Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 108091058560 IL8 Proteins 0.000 description 3
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000002331 protein detection Methods 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 241000160765 Erebia ligea Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 210000001501 megacaryocyte Anatomy 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000013139 quantization Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 101150010856 CRT gene Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000951342 Homo sapiens Dickkopf-related protein 3 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000613820 Homo sapiens Osteopontin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108700012441 IGF2 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000009774 resonance method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2010903140 | 2010-07-14 | ||
| AU2010903140A AU2010903140A0 (en) | 2010-07-14 | Diagnostic for colorectal cancer | |
| CN201180034158.5A CN103140760B (zh) | 2010-07-14 | 2011-07-14 | 结肠直肠癌的诊断 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180034158.5A Division CN103140760B (zh) | 2010-07-14 | 2011-07-14 | 结肠直肠癌的诊断 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105755112A CN105755112A (zh) | 2016-07-13 |
| CN105755112B true CN105755112B (zh) | 2019-06-07 |
Family
ID=45468816
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511009181.5A Active CN105755112B (zh) | 2010-07-14 | 2011-07-14 | 结肠直肠癌的诊断 |
| CN201180034158.5A Active CN103140760B (zh) | 2010-07-14 | 2011-07-14 | 结肠直肠癌的诊断 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180034158.5A Active CN103140760B (zh) | 2010-07-14 | 2011-07-14 | 结肠直肠癌的诊断 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130345322A1 (enExample) |
| EP (2) | EP2829881B1 (enExample) |
| JP (1) | JP6061344B2 (enExample) |
| CN (2) | CN105755112B (enExample) |
| AU (1) | AU2011279555B2 (enExample) |
| BR (1) | BR112013000745B1 (enExample) |
| DK (1) | DK2829881T3 (enExample) |
| ES (1) | ES2653646T3 (enExample) |
| IN (1) | IN2013CN01129A (enExample) |
| NO (1) | NO2829881T3 (enExample) |
| PT (1) | PT2829881T (enExample) |
| RU (1) | RU2013103995A (enExample) |
| WO (1) | WO2012006681A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2829881T3 (en) * | 2010-07-14 | 2017-12-04 | Vision Tech Bio Pty Ltd | Colorectal cancer diagnostic |
| US9141756B1 (en) | 2010-07-20 | 2015-09-22 | University Of Southern California | Multi-scale complex systems transdisciplinary analysis of response to therapy |
| WO2012106556A2 (en) | 2011-02-02 | 2012-08-09 | Amgen Inc. | Methods and compositons relating to inhibition of igf-1r |
| JP6298054B2 (ja) | 2012-08-09 | 2018-03-20 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 心不全の診断 |
| GB201218341D0 (en) * | 2012-10-12 | 2012-11-28 | Orign Sciences Ltd | Diagnostic method |
| JP2017520775A (ja) * | 2014-03-28 | 2017-07-27 | アプライド プロテオミクス，インク． | 結腸直腸腫瘍を検出するためのタンパク質バイオマーカープロファイル |
| ES2732925T3 (es) * | 2014-07-18 | 2019-11-26 | Sanofi Sa | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer |
| CN106191215B (zh) * | 2015-04-29 | 2020-03-24 | 中国科学院上海生命科学研究院 | 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用 |
| TWI728975B (zh) * | 2015-05-12 | 2021-06-01 | 英屬維爾京群島商遠東超級實驗室有限公司 | 鑒定對腫瘤具有直接抑制作用的干擾素的方法及其用途 |
| CN105219844B (zh) * | 2015-06-08 | 2018-12-14 | 华夏京都医疗投资管理有限公司 | 一种筛查十一种疾病的基因标志物组合、试剂盒以及疾病风险预测模型 |
| CN105021828B (zh) * | 2015-07-20 | 2017-07-28 | 上海交通大学医学院附属新华医院 | 通过检测三期结直肠肿瘤患者血清预测肿瘤患者预后 |
| CN105567846A (zh) * | 2016-02-14 | 2016-05-11 | 上海交通大学医学院附属仁济医院 | 检测粪便中细菌dna的试剂盒及其在大肠癌诊断中的应用 |
| JP6984862B2 (ja) * | 2017-03-15 | 2021-12-22 | 国立大学法人金沢大学 | 血中ケモカインをマーカーとして用いた大腸癌の検出 |
| CN107164535A (zh) * | 2017-07-07 | 2017-09-15 | 沈阳宁沪科技有限公司 | 一种无创高通量甲基化结肠癌诊断、研究和治疗方法 |
| CN110540588B (zh) * | 2018-05-28 | 2022-08-23 | 香港中文大学 | 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用 |
| CN108957014A (zh) * | 2018-09-27 | 2018-12-07 | 郑州大学第附属医院 | 结直肠癌血清标志物、表达评估方法、试剂盒及应用 |
| EP3870030A4 (en) * | 2018-10-23 | 2022-08-03 | Blackthorn Therapeutics, Inc. | SYSTEMS AND METHODS FOR SCREENING, DIAGNOSIS AND STRATIFICATION OF PATIENTS |
| CN109504778B (zh) * | 2019-01-11 | 2021-11-09 | 复旦大学附属中山医院 | 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型 |
| EP3931571B1 (en) * | 2019-03-01 | 2023-06-07 | Advanced Marker Discovery, S.L. | Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof |
| JP7300660B2 (ja) * | 2019-04-03 | 2023-06-30 | 京都府公立大学法人 | 大腸がんの検出方法 |
| JP7032764B2 (ja) * | 2019-04-03 | 2022-03-09 | 京都府公立大学法人 | 大腸がんの検出方法 |
| GB201906199D0 (en) * | 2019-05-02 | 2019-06-19 | Belgian Volition Sprl | Method for the detection of cancer |
| US20220378877A1 (en) * | 2019-11-13 | 2022-12-01 | University Of Virginia Patent Foundation | Treatment of clostridium difficile infections |
| EP3835789A1 (en) | 2019-12-13 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Biomarker panel for diagnosing colorectal cancer |
| WO2022130597A1 (ja) * | 2020-12-18 | 2022-06-23 | 国立大学法人東北大学 | 推定装置、推定方法、推定プログラム、生成装置、及び、推定システム |
| WO2022140116A1 (en) * | 2020-12-21 | 2022-06-30 | Freenome Holdings, Inc. | Markers for the early detection of colon cell proliferative disorders |
| US20240393336A1 (en) * | 2021-04-20 | 2024-11-28 | Vision Tech Bio Pty Ltd | Biomarkers for colorectal cancer |
| EP4384830A4 (en) * | 2021-08-11 | 2025-09-24 | Vision Tech Bio Pty Ltd | METHOD FOR DETECTING ADENOMA |
| WO2023128419A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 이노제닉스 | 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용 |
| WO2023128429A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 이노제닉스 | 대장암 및 진행 선종의 선별 검사 방법 및 그 응용 |
| CN114594259B (zh) * | 2022-04-22 | 2022-09-13 | 北京易科拜德科技有限公司 | 一种新型的用于结直肠癌预后预测和诊断的模型及其应用 |
| PL441319A1 (pl) * | 2022-05-31 | 2023-12-04 | Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu | Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro |
| CN116219007A (zh) * | 2022-09-15 | 2023-06-06 | 绍兴积准生物科技有限公司 | 检测结直肠癌的生物标志物组及其应用 |
| CN119688988A (zh) * | 2024-11-25 | 2025-03-25 | 中国医学科学院肿瘤医院 | Timp1和foxp3作为诊断结直肠癌的生物标志物组合及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009037572A2 (en) * | 2007-06-04 | 2009-03-26 | Diagnoplex | Biomarker combinations for colorectal cancer |
| WO2009126543A1 (en) * | 2008-04-08 | 2009-10-15 | Nuclea Biomarkers, Llc | Biomarker panel for prediction of recurrent colorectal cancer |
| EP2145190A1 (en) * | 2007-05-10 | 2010-01-20 | Roche Diagnostics GmbH | Use of timp-1 as a marker for colorectal cancer |
| CN103140760B (zh) * | 2010-07-14 | 2016-01-27 | 联邦科学与工业研究组织 | 结肠直肠癌的诊断 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| JP2004198419A (ja) * | 2002-12-13 | 2004-07-15 | Bayer Healthcare Llc | Ｔｉｍｐ１を用いた検出方法 |
| US20050014165A1 (en) * | 2003-07-18 | 2005-01-20 | California Pacific Medical Center | Biomarker panel for colorectal cancer |
| ATE491953T1 (de) * | 2003-09-15 | 2011-01-15 | Oklahoma Med Res Found | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis |
| BRPI0401830A (pt) | 2004-05-25 | 2006-01-17 | Bentonit Uniao Nordeste Sa | Processo de produção de pós granulados secos |
| JP5399900B2 (ja) * | 2006-06-30 | 2014-01-29 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｉｇｆｂｐ２インヒビター |
| WO2008073660A1 (en) | 2006-11-09 | 2008-06-19 | University Of Washington | Molecules and methods for treatment and detection of cancer |
| WO2008079269A2 (en) * | 2006-12-19 | 2008-07-03 | Genego, Inc. | Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom |
| JP2010517582A (ja) | 2007-02-12 | 2010-05-27 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 結腸癌の早期検出および予後診断の方法 |
| RU2489720C2 (ru) * | 2007-02-27 | 2013-08-10 | Сентоклон Интернэшнл Аб | Мультиплексная детекция опухолевых клеток с использованием панели агентов, связывающихся с внеклеточными маркерами |
| WO2008116178A2 (en) * | 2007-03-21 | 2008-09-25 | Vanderbilt University | Systems and methods for diagnosis and prognosis of colorectal cancer |
| WO2008144345A2 (en) * | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| US20090017463A1 (en) * | 2007-07-10 | 2009-01-15 | Vanderbilt University | Methods for predicting prostate cancer recurrence |
| US20100111969A1 (en) * | 2008-10-31 | 2010-05-06 | Apogenix Gmbh | Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors |
| CA2745376A1 (en) * | 2008-12-01 | 2010-06-10 | Lifespan Extension Llc | Methods and compositions for altering health, wellbeing, and lifespan |
| CA2745961A1 (en) * | 2008-12-04 | 2010-06-10 | The Regents Of The University Of California | Materials and methods for determining diagnosis and prognosis of prostate cancer |
| CN102326080B (zh) * | 2009-02-20 | 2015-08-05 | 加利福尼亚大学董事会 | A+生物标志物的试验 |
| US20110177525A1 (en) * | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
-
2011
- 2011-07-14 DK DK14178981.8T patent/DK2829881T3/en active
- 2011-07-14 US US13/809,785 patent/US20130345322A1/en not_active Abandoned
- 2011-07-14 CN CN201511009181.5A patent/CN105755112B/zh active Active
- 2011-07-14 CN CN201180034158.5A patent/CN103140760B/zh active Active
- 2011-07-14 EP EP14178981.8A patent/EP2829881B1/en active Active
- 2011-07-14 NO NO14178981A patent/NO2829881T3/no unknown
- 2011-07-14 AU AU2011279555A patent/AU2011279555B2/en active Active
- 2011-07-14 BR BR112013000745-1A patent/BR112013000745B1/pt not_active IP Right Cessation
- 2011-07-14 PT PT141789818T patent/PT2829881T/pt unknown
- 2011-07-14 JP JP2013518909A patent/JP6061344B2/ja active Active
- 2011-07-14 RU RU2013103995/15A patent/RU2013103995A/ru not_active Application Discontinuation
- 2011-07-14 WO PCT/AU2011/000895 patent/WO2012006681A1/en not_active Ceased
- 2011-07-14 EP EP11806149.8A patent/EP2593795A4/en not_active Withdrawn
- 2011-07-14 IN IN1129CHN2013 patent/IN2013CN01129A/en unknown
- 2011-07-14 ES ES14178981.8T patent/ES2653646T3/es active Active
-
2017
- 2017-03-28 US US15/471,147 patent/US10877039B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2145190A1 (en) * | 2007-05-10 | 2010-01-20 | Roche Diagnostics GmbH | Use of timp-1 as a marker for colorectal cancer |
| WO2009037572A2 (en) * | 2007-06-04 | 2009-03-26 | Diagnoplex | Biomarker combinations for colorectal cancer |
| WO2009126543A1 (en) * | 2008-04-08 | 2009-10-15 | Nuclea Biomarkers, Llc | Biomarker panel for prediction of recurrent colorectal cancer |
| CN103140760B (zh) * | 2010-07-14 | 2016-01-27 | 联邦科学与工业研究组织 | 结肠直肠癌的诊断 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013000745A2 (pt) | 2016-05-24 |
| IN2013CN01129A (enExample) | 2015-07-31 |
| CN103140760B (zh) | 2016-01-27 |
| BR112013000745B1 (pt) | 2021-02-02 |
| AU2011279555B2 (en) | 2016-10-20 |
| EP2829881A2 (en) | 2015-01-28 |
| US20170205414A1 (en) | 2017-07-20 |
| AU2011279555A1 (en) | 2013-01-31 |
| EP2829881B1 (en) | 2017-08-23 |
| CN103140760A (zh) | 2013-06-05 |
| PT2829881T (pt) | 2017-11-29 |
| EP2829881A3 (en) | 2015-05-13 |
| JP6061344B2 (ja) | 2017-01-18 |
| RU2013103995A (ru) | 2014-08-20 |
| ES2653646T3 (es) | 2018-02-08 |
| CN105755112A (zh) | 2016-07-13 |
| DK2829881T3 (en) | 2017-12-04 |
| JP2013533977A (ja) | 2013-08-29 |
| NO2829881T3 (enExample) | 2018-01-20 |
| WO2012006681A1 (en) | 2012-01-19 |
| US10877039B2 (en) | 2020-12-29 |
| EP2593795A1 (en) | 2013-05-22 |
| US20130345322A1 (en) | 2013-12-26 |
| EP2593795A4 (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105755112B (zh) | 结肠直肠癌的诊断 | |
| US8586006B2 (en) | Organ-specific proteins and methods of their use | |
| CN103582815A (zh) | 用于卵巢癌的生物标志物组、诊断方法和测试试剂盒 | |
| JP2010500568A5 (enExample) | ||
| CN112345755A (zh) | 乳腺癌的生物标志物及其应用 | |
| CN113439212B (zh) | 用于确定侵袭性前列腺癌的生物标志物组合 | |
| KR20100126258A (ko) | 부인과 질환을 탐지하기 위한 분석법 | |
| KR102208140B1 (ko) | 전립선암의 바이오마커 검출에서 사용하기 위한 방법 및 어레이 | |
| KR102018205B1 (ko) | 대장암 진단용 조성물 및 상기 조성물을 이용한 대장암 진단 방법 | |
| CN118251595A (zh) | 检测腺瘤的方法 | |
| CN117120847A (zh) | 肺癌的检测方法 | |
| US20240393336A1 (en) | Biomarkers for colorectal cancer | |
| KR102018209B1 (ko) | 위암 진단용 조성물 및 상기 조성물을 이용한 위암 진단 방법 | |
| CN116413430B (zh) | 一种用于肝癌早期预测的自身抗体/抗原组合及检测试剂盒 | |
| KR102903735B1 (ko) | 담관암종의 표지자로서의 timp1 | |
| KR101652894B1 (ko) | 대장암에 대한 신규 바이오마커 및 그의 용도 | |
| JP2023550278A (ja) | 胆管癌のマーカーとしてのｔｉｍｐ１ | |
| CN117129681A (zh) | 乳腺癌相关的生物标志物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20181107 Address after: Vitoria, Australia Applicant after: Visual technology biology Pte Ltd Address before: Campbell, Australian Capital Applicant before: Commonwealth Scientific and Industrial Research Organisation |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |